ICLR
ICON Public Limited Company NASDAQ Listed May 15, 1998$125.03
Mkt Cap $9.5B
52w Low $66.57
40.5% of range
52w High $211.00
50d MA $107.96
200d MA $155.87
P/E (TTM)
11.8x
EV/EBITDA
13.0x
P/B
1.0x
Debt/Equity
0.4x
ROE
8.5%
P/FCF
15.5x
RSI (14)
—
ATR (14)
—
Beta
1.28
50d MA
$107.96
200d MA
$155.87
Avg Volume
2.0M
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
South County Business Park · Dublin, L2 18 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | 3.19 | 3.28 | +2.8% | 116.17 | -0.9% | +1.9% | -4.6% | -0.8% | +8.4% | +2.3% | — |
| Oct 22, 2025 | AMC | 3.28 | 3.31 | +0.9% | 192.60 | -1.9% | -6.5% | -1.1% | +2.2% | -2.4% | -6.6% | — |
| Jul 23, 2025 | AMC | 3.19 | 3.26 | +2.2% | 167.89 | +20.3% | +16.2% | -4.1% | +1.4% | -2.3% | -2.0% | — |
| Apr 30, 2025 | AMC | 3.11 | 3.19 | +2.6% | 151.44 | -5.8% | -4.1% | -1.5% | +0.0% | -5.5% | +2.8% | — |
| Feb 19, 2025 | AMC | 3.41 | 3.43 | +0.6% | 191.32 | +1.9% | +5.5% | -0.2% | -1.1% | -0.8% | -0.7% | — |
| Oct 23, 2024 | AMC | 3.85 | 3.35 | -13.0% | 280.76 | -14.3% | -21.0% | -0.6% | +4.5% | +0.8% | -1.9% | — |
| Jul 24, 2024 | AMC | 3.68 | 3.75 | +1.9% | 331.77 | -6.6% | -5.6% | +3.3% | +1.8% | +0.4% | -0.6% | — |
| Apr 24, 2024 | AMC | 3.41 | 3.47 | +1.8% | 309.44 | +0.9% | -3.0% | +2.7% | -1.4% | -2.1% | +1.3% | — |
| Feb 21, 2024 | AMC | 3.44 | 3.46 | +0.6% | 284.70 | +5.9% | +10.1% | +0.3% | +1.4% | +1.2% | +0.3% | — |
| Oct 25, 2023 | AMC | 3.28 | 3.30 | +0.6% | 225.28 | +5.5% | +6.8% | -2.2% | +1.2% | +2.4% | +2.5% | — |
| Jul 26, 2023 | AMC | 3.08 | 3.11 | +1.0% | 253.10 | -3.9% | -4.5% | +4.3% | -0.3% | -0.9% | +0.9% | — |
| Apr 26, 2023 | AMC | 2.88 | 2.90 | +0.7% | 200.88 | +0.8% | -5.1% | +1.0% | +1.4% | -3.9% | -1.1% | — |
| Feb 22, 2023 | AMC | 3.06 | 3.13 | +2.3% | 221.71 | +2.8% | +0.6% | +0.2% | -0.2% | +1.1% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | BMO Capital | Upgrade | Market Perform → Outperform | — | $99.99 | $101.63 | +1.6% | +3.1% | -1.0% | +3.0% | +5.3% | +0.7% |
| Mar 11 | Citigroup | Maintains | Neutral → Neutral | — | $106.62 | $107.12 | +0.5% | -1.2% | -7.5% | +0.9% | -0.7% | +3.0% |
| Mar 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $107.20 | $105.77 | -1.3% | +2.6% | -3.1% | -1.2% | -7.5% | +0.9% |
| Feb 23 | Jefferies | Upgrade | Hold → Buy | — | $99.70 | $100.68 | +1.0% | +5.0% | -0.5% | -3.0% | +5.1% | +1.9% |
| Feb 18 | TD Cowen | Upgrade | Hold → Buy | — | $88.62 | $89.26 | +0.7% | +8.9% | +2.0% | +1.3% | +5.0% | -0.5% |
| Jan 22 | TD Cowen | Maintains | Hold → Hold | — | $184.87 | $187.95 | +1.7% | +1.0% | -0.0% | +0.4% | +0.3% | -0.9% |
| Jan 8 | Truist | Downgrade | Buy → Hold | — | $202.92 | $179.07 | -11.8% | -7.2% | -3.6% | -0.7% | +1.7% | +0.8% |
| Dec 15 | Barclays | Maintains | Equal Weight → Equal Weight | — | $186.58 | $184.94 | -0.9% | -1.2% | -1.0% | -1.7% | -0.4% | -2.8% |
| Oct 24 | Barclays | Maintains | Equal Weight → Equal Weight | — | $180.00 | $179.22 | -0.4% | -1.1% | +2.2% | -2.4% | -6.6% | -0.4% |
| Oct 24 | TD Cowen | Maintains | Hold → Hold | — | $180.00 | $179.22 | -0.4% | -1.1% | +2.2% | -2.4% | -6.6% | -0.4% |
| Oct 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $192.31 | $190.26 | -1.1% | +0.3% | +0.5% | -1.8% | -2.0% | -0.1% |
| Sep 9 | Jefferies | Downgrade | Buy → Hold | — | $177.81 | $171.08 | -3.8% | -5.0% | -2.1% | +5.8% | -0.1% | -2.6% |
| Sep 3 | Rothschild & Co | Upgrade | Neutral → Buy | — | $177.84 | $182.05 | +2.4% | +1.2% | -2.0% | -0.8% | +1.7% | -5.0% |
| Sep 2 | Baird | Maintains | Outperform → Outperform | — | $177.94 | $176.65 | -0.7% | -0.1% | +1.2% | -2.0% | -0.8% | +1.7% |
| Aug 21 | Citigroup | Downgrade | Buy → Neutral | — | $180.25 | $177.01 | -1.8% | -2.5% | +0.1% | -2.3% | +0.0% | +1.3% |
| Jul 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $195.01 | $193.41 | -0.8% | -4.1% | +1.4% | -2.3% | -2.0% | -6.8% |
| Jul 25 | UBS | Maintains | Buy → Buy | — | $195.01 | $193.41 | -0.8% | -4.1% | +1.4% | -2.3% | -2.0% | -6.8% |
| Jul 25 | Truist | Maintains | Buy → Buy | — | $195.01 | $193.41 | -0.8% | -4.1% | +1.4% | -2.3% | -2.0% | -6.8% |
| Jul 25 | Mizuho | Maintains | Outperform → Outperform | — | $195.01 | $193.41 | -0.8% | -4.1% | +1.4% | -2.3% | -2.0% | -6.8% |
| Jul 25 | Barclays | Maintains | Equal Weight → Equal Weight | — | $195.01 | $193.41 | -0.8% | -4.1% | +1.4% | -2.3% | -2.0% | -6.8% |
| Jul 24 | Baird | Upgrade | Neutral → Outperform | — | $167.89 | $202.04 | +20.3% | +16.2% | -4.1% | +1.4% | -2.3% | -2.0% |
| Jul 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $151.58 | $152.85 | +0.8% | -0.7% | +1.0% | -1.0% | -0.7% | -2.6% |
| May 15 | Mizuho | Maintains | Outperform → Outperform | — | $132.23 | $131.41 | -0.6% | -1.2% | +0.7% | -0.7% | +1.0% | -4.1% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $145.21 | $148.32 | +2.1% | -1.5% | +0.0% | -5.5% | +2.8% | -0.3% |
| May 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $145.21 | $148.32 | +2.1% | -1.5% | +0.0% | -5.5% | +2.8% | -0.3% |
| May 2 | Baird | Maintains | Neutral → Neutral | — | $145.21 | $148.32 | +2.1% | -1.5% | +0.0% | -5.5% | +2.8% | -0.3% |
| Apr 29 | JP Morgan | Downgrade | Overweight → Neutral | — | $145.00 | $142.89 | -1.5% | +3.0% | +1.4% | -4.1% | -1.5% | +0.0% |
| Apr 14 | TD Cowen | Downgrade | Buy → Hold | — | $144.04 | $144.54 | +0.3% | +1.9% | -1.1% | -1.1% | -2.9% | -1.5% |
| Apr 10 | Barclays | Downgrade | Overweight → Equal Weight | — | $155.49 | $148.51 | -4.5% | -8.3% | +1.0% | +1.9% | -1.1% | -1.1% |
| Apr 10 | Truist | Maintains | Buy → Buy | — | $155.49 | $148.51 | -4.5% | -8.3% | +1.0% | +1.9% | -1.1% | -1.1% |
| Apr 9 | Mizuho | Maintains | Outperform → Outperform | — | $142.50 | $141.08 | -1.0% | +9.1% | -8.3% | +1.0% | +1.9% | -1.1% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $153.72 | $149.22 | -2.9% | -1.9% | -5.5% | +9.1% | -8.3% | +1.0% |
| Mar 21 | Goldman Sachs | Downgrade | Buy → Neutral | — | $183.96 | $177.92 | -3.3% | +0.5% | -0.2% | -2.9% | -0.1% | +0.7% |
| Mar 4 | Baird | Maintains | Neutral → Neutral | — | $184.81 | $184.71 | -0.1% | -0.6% | +1.6% | -0.7% | +0.7% | -2.1% |
| Feb 21 | Barclays | Maintains | Overweight → Overweight | — | $201.84 | $204.68 | +1.4% | -0.2% | -1.1% | -0.8% | -0.7% | -3.3% |
| Feb 13 | Truist | Maintains | Buy → Buy | — | $186.53 | $186.25 | -0.2% | -2.1% | +2.0% | +1.3% | +1.4% | +5.5% |
| Feb 3 | JP Morgan | Maintains | Overweight → Overweight | — | $199.08 | $194.19 | -2.5% | -1.8% | -1.1% | +1.6% | -0.2% | -1.3% |
| Jan 15 | RBC Capital | Maintains | Outperform → Outperform | — | $200.24 | $204.19 | +2.0% | -0.4% | +1.5% | -2.2% | +3.5% | -1.0% |
| Jan 14 | William Blair | Maintains | Outperform → Outperform | — | $217.99 | $199.39 | -8.5% | -8.1% | -0.4% | +1.5% | -2.2% | +3.5% |
| Jan 6 | Citigroup | Maintains | Buy → Buy | — | $213.28 | $214.11 | +0.4% | +1.0% | +3.3% | -1.5% | -0.5% | -0.1% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $203.26 | $203.93 | +0.3% | +0.6% | +0.1% | +1.4% | +1.2% | +1.5% |
| Nov 20 | Baird | Maintains | Neutral → Neutral | — | $195.60 | $196.67 | +0.5% | +4.1% | +4.5% | +0.7% | +1.2% | -2.1% |
| Nov 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $187.22 | $186.79 | -0.2% | +4.5% | +4.1% | +4.5% | +0.7% | +1.2% |
| Oct 28 | Truist | Maintains | Buy → Buy | — | $220.47 | $221.26 | +0.4% | +4.5% | +0.8% | -1.9% | -2.5% | -0.8% |
| Oct 25 | Leerink Partners | Maintains | Outperform → Outperform | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
| Oct 25 | JP Morgan | Maintains | Overweight → Overweight | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
| Oct 25 | TD Cowen | Maintains | Buy → Buy | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
| Oct 25 | Goldman Sachs | Maintains | Buy → Buy | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
| Oct 25 | Baird | Maintains | Neutral → Neutral | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
| Oct 25 | Barclays | Maintains | Overweight → Overweight | — | $221.73 | $224.79 | +1.4% | -0.6% | +4.5% | +0.8% | -1.9% | -2.5% |
No insider trades available.
No recent filings available.
Data updated apr 25, 2026 2:52pm
· Source: massive.com